CEO and Founder: Daniel Katzman
Daniel has over twenty years of international biotech experience with novel drug programs, fund raising, and business development. He is the founder and President of NeuroHealing Pharmaceuticals (Boston, MA), the past Vice President of Oridion Medical, and a venture partner with Axia Ventures Company Builder. Building and managing the unique start-up challenges that biotech start-up companies face gives Unleash a key advantage in leveraging its critical assets to the finish line. Daniel obtained his MSc in Biochemistry at the Universidad Nacional de La Plata.
COO: Louis J. Cantolupo
Experienced in the development of product concepts to the clinic, Lou has over 20 years of international business and product development in both the gene therapy and vaccine space. As a founder of the CMO Omnia Biologics (acquired by Vigene Biosciences) and having worked with novel production technologies throughout his career at GenVec, Crucell, and Valneva, Lou has a level of perspective that complements the unique development needs of innovative biopharmaceutical products. Lou has an MBA from the University of Maryland College Park (Smith School of Business) and a BS in Biotechnology from the Rochester Institute of Technology.
Vice President, Preclinical Development: Bradley Keller, PhD
With a long and spanning career in preclinical development, Brad provides Unleash the know-how needed to successfully translate the science into the clinic. Having worked at Pfizer, Sigma Aldrich, and in venture capital (RiverVest Venture Partners), Brad brings the know-how needed to convert Unleash’s concepts to reality through managing the company’s preclinical efforts internally and with external contractors. Brad holds a PhD in Biochemistry from the University of Kansas and a BA in Biology and Chemistry from the University of Delaware.